Pfizer Reviews German Investment Over Drug Price Policies
CEO Albert Bourla warned Chancellor Friedrich Merz that government proposals to lower drug prices threaten long-term predictability. The company is now reviewing the timing and scope of its planned investments in Germany following similar pullbacks by Eli Lilly and Boehringer Ingelheim.
Xurve View
洞察:
Xurve View
PFIZER INC is reviewing its planned investments in Germany after government proposals to lower drug prices. This review follows similar investment cuts by ELI LILLY & CO and Boehringer Ingelheim. CEO Albert Bourla warned that the policies threaten the predictability required for long-term pharmaceutical commitments.
